|
|
| (22 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Fosinopril]] |
| |authorTag={{AZ}}, {{AM}}
| |
| |genericName=Fosinopril
| |
| |aOrAn=an
| |
| |drugClass=Angiontensin converting enzyme inhibitor
| |
| |indication=[[hypertension]], [[heart failure]]
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=[[hypotension]] (2.4% to 4.4%), [[hyperkalemia]] (2.6% ), [[dizziness]] (1.6% to 11.9% ), [[cough]] (2.2% to 9.7%).
| |
| |blackBoxWarningTitle=USE IN PREGNANCY
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, enalapril maleate should be discontinued as soon as possible.
| |
| |fdaLIADAdult=<h4>Condition 1</h5>
| |
| | |
| * Dosing Information
| |
| | |
| :: (Dosage)
| |
| }}
| |